The Dexlansoprazole market is expected to witness steady growth through 2031, driven by the increasing prevalence of gastroesophageal reflux disease (GERD), rising healthcare awareness, and expanding global access to advanced gastrointestinal therapies. As proton pump inhibitors remain a cornerstone in acid-related disorder treatment, the demand for effective and long-lasting medications...